<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) is a systemic disorder of the connective tissues caused by insufficient fibrillin-1 microfibril formation and can cause cardiac complications, <z:hpo ids='HP_0002097'>emphysema</z:hpo>, ocular <z:hpo ids='HP_0001083'>lens dislocation</z:hpo> and severe <z:e sem="disease" ids="C0031090" disease_type="Disease or Syndrome" abbrv="">periodontal disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>ADAMTSL6β, a microfibril-associated extracellular matrix protein that has been implicated in fibrillin-1 microfibril assembly is able to improve microfibril insufficiency in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> mice model </plain></SENT>
<SENT sid="2" pm="."><plain>These findings suggest a new therapeutic strategy for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> through ADAMTSL6β-mediated fibrillin-1 microfibril assembly </plain></SENT>
<SENT sid="3" pm="."><plain>We here review effect on ADAMTSL6β to the improvement of microfibril insufficiency in periodontal tissue as a model </plain></SENT>
</text></document>